Research
Epitranscriptomics & Cancer Adaptation : A.David

Activities

Our research work focuses on the contribution of post-transcriptional mechanisms on cancer cell adaptation, in particular RNA epigenetic & translational control.

More..

Zotero public









Cancel


21 Items
Title  Creator  Group name  Publishing year 
National multicentric evaluation of quality of pathology reports for rectal cancer in France in 2016 Boutanos et al. EquipeMY May 2019
ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research Marchiò et al. EquipeMY 09 01, 2019
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach Luchini et al. EquipeMY May 06, 2019
The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry Villeneuve et al. EquipePM 02 17, 2017
Molecular subtypes of metastatic colorectal cancer are associated with patient response to irinotecan-based therapies Del Rio et al. EquipePM Mar 08 2017
Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study Valmary-Degano et al. EquipePM Oct 2017
Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function Guiu et al. EquipePM Jan 18 2017
Clinical and molecular characterisation of hereditary and sporadic metastatic colorectal cancers harbouring microsatellite instability/DNA mismatch repair deficiency Cohen et al. EquipeMY 11 2017
Antibody targeting of claudin-1 as a potential colorectal cancer therapy Cherradi et al. EquipeMY 06 28, 2017
Diffuse malignant peritoneal mesothelioma: Evaluation of systemic chemotherapy with comprehensive treatment through the RENAPE Database: Multi-Institutional Retrospective Study Kepenekian et al. EquipePM Jul 26 2016
Professional risks when carrying out cytoreductive surgery for peritoneal malignancy with hyperthermic intraperitoneal chemotherapy (HIPEC): A French multicentric survey Ferron et al. EquipePM Oct 2015
Ovarian carcinoma patient derived xenografts reproduce their tumor of origin and preserve an oligoclonal structure Colombo et al. EquipeCTCS Sep 29 2015
Outcomes of special histotypes of breast cancer after adjuvant endocrine therapy with letrozole or tamoxifen in the monotherapy cohort of the BIG 1-98 trial Munzone et al. EquipeMY Dec 2015
High EGFR protein expression and exon 9 PIK3CA mutations are independent prognostic factors in triple negative breast cancers Jacot et al. EquipeCTCS 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipePM May 20 2015
Dual targeting of HER1/EGFR and HER2 with cetuximab and trastuzumab in patients with metastatic pancreatic cancer after gemcitabine failure: results of the "THERAPY"phase 1-2 trial Assenat et al. EquipeAP May 20 2015
The human Mullerian inhibiting substance type II receptor as immunotherapy target for ovarian cancer. Validation using the mAb 12G4 Kersual et al. EquipeMY 2014
Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial Samalin et al. EquipeMY Mar 4 2014
Prognostic impact of the inclusion of uPA/PAI-1 tumor levels in the current adjuvant treatment decision-making for early breast cancer Saadoun et al. EquipeCTCS Feb 2014
Impact of chromosomal instability on colorectal cancer progression and outcome Orsetti et al. EquipeMY 2014
Clinical validation of the detection of KRAS and BRAF mutations from circulating tumor DNA Thierry et al. EquipeMY Apr 2014
21 Items


Who are we ?

Located in the Parc Euromédecine, the Institut de Recherche en Cancérologie de Montpellier (U1194) is located on the Val d'Aurelle Campus (ICM, Institut régional du Cancer Montpellier/ Val d'Aurelle).

U1194 Research Centre supported by Inserm, the University of Montpellier and the Institut du Cancer de Montpellier (ICM)

More                                                                                                                 Join us

Contact us

Institut de Recherche en Cancérologie de
Montpellier (U1194) - Campus Val d'Aurelle

208 avenue des Apothicaires
34298 Montpellier cedex 5 FRANCE

 

insermUM1ICM

© Institut de Recherche en Cancérologie de Montpellier - 2011 - Tous droits réservés - Mentions légales - Connexion - Conception : ID Alizés